Loading the session
Loading the session
Loading instrument
$7.14
+0.00%Delayed · Pre-marketDelayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 06:26 IST · A quote does not mean the product is available to trade on your account.
Opens 8:00 pm IST
Opens 8:00 pm IST
Opens 8:00 pm IST
In brief
Questions investors ask
Quotes run fifteen minutes behind.
1 month: −2.7% (SPY −1.6%, XLV +13.5%). 3 months: −16.0% (SPY −0.4%, XLV +15.5%). 1 year: −34.5% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: OCUL, SPY and XLV · as of 4 Nov 2026
28.8M shares were sold short at the 15 Oct 2026 settlement, 13.1% of the 219.6M shares outstanding; covering them would take 8.1 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
The 4 Nov 2026 close of $7.14 was 16.7% below its 50-day average ($8.57) and 21.1% below its 200-day average ($9.05). It has closed below the 200-day for 30 sessions, since 24 Sep 2026. The 50-day average crossed below the 200-day on 23 Oct 2026, 8 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
Closed at $7.14 on 4 Nov 2026: 56.6% below the 52-week high of $16.44 (8 Dec 2025) and 19.0% above the low of $6.00 (19 Oct 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026
Price return, split-adjusted
At the 4 Nov 2026 close
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
December 8, 2025
+28.06%February 22, 2024
+28.99%February 13, 2023
+35.14%